Extended time frame for restoring inner ear function through gene therapy in Usher1G preclinical model
JCI Insight · 08.02.2024 · 9 (3)
DOI: 10.1172/jci.insight.169504 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, online erschienen am 08.02.2024. Verfasst von Ghizlene Lahlou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institut Pasteur, Université Paris Cité, Inserm, Institut de l'Audition, Paris, France. Hauptthemen laut MEDLINE: Usher Syndromes, Vestibule, Labyrinth. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FPA, Centre National d’Etudes Spatiales, ANR.
Abstract (Originalsprache)
Neonatal gene therapy has been shown to prevent inner ear dysfunction in mouse models of Usher syndrome type I (USH1), the most common genetic cause of combined deafness-blindness and vestibular dysfunction. However, hearing onset occurs after birth in mice and in utero in humans, making it questionable how to transpose murine gene therapy outcomes to clinical settings. Here, we sought to extend the therapeutic time window in a mouse model for USH1G to periods corresponding to human neonatal stages, more suitable for intervention in patients. Mice with deletion of Ush1g ( Ush1g –/– ) were subjected to gene therapy after the hearing onset. The rescue of inner ear hair cell structure was evaluated by confocal imaging and electron microscopy. Hearing and vestibular function were assessed by recordings of the auditory brain stem response and vestibulo-ocular reflex and by locomotor tests. Up to P21, gene therapy significantly restored both the hearing and balance deficits in Ush1g –/– mice. However, beyond this age and up to P30, vestibular function was restored but not hearing. Our data show that effective gene therapy is possible in Ush1g –/– mice well beyond neonatal stages, implying that the therapeutic window for USH1G may be wide enough to be transposable to newborn humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institut Pasteur, Université Paris Cité, Inserm, Institut de l'Audition, Paris, France.
- Assistance Publique-Hôpitaux de Paris, Sorbonne University, Service d'ORL et de Chirurgie Cervico-Faciale, DMU ChIR, Paris, France.
- Université Paris Cité, Faculté de Médecine, Paris, France.
- Université Paris Cité, CNRS UMR 8002, INCC - Integrative Neuroscience and Cognition Center, Paris, France.
- Department of Pediatric Otolaryngology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, France.
- Institut Pasteur, INSERM, Pathogenesis of Vascular Infections Unit, Paris, France.
Förderung
- FPA
- Centre National d’Etudes Spatiales
- ANR
Zitieren
APA
Lahlou, G., Calvet, C., Simon, F., Michel, V., Alciato, L., Plion, B., Boutet de Monvel, J., Lecomte, M. J., Beraneck, M., Petit, C., & Safieddine, S. (2024). Extended time frame for restoring inner ear function through gene therapy in Usher1G preclinical model. JCI Insight, 9(3). https://doi.org/10.1172/jci.insight.169504
Vancouver
Lahlou G, Calvet C, Simon F, Michel V, Alciato L, Plion B, et al. Extended time frame for restoring inner ear function through gene therapy in Usher1G preclinical model. JCI Insight. 2024;9(3). doi:10.1172/jci.insight.169504
BibTeX
@article{Lahlou2024,
author = {Lahlou, Ghizlene and Calvet, Charlotte and Simon, François and Michel, Vincent and Alciato, Lauranne and Plion, Baptiste and Boutet de Monvel, Jacques and Lecomte, Marie-José and Beraneck, Mathieu and Petit, Christine and Safieddine, Saaid},
title = {Extended time frame for restoring inner ear function through gene therapy in Usher1G preclinical model},
journal = {JCI Insight},
year = {2024},
volume = {9},
number = {3},
doi = {10.1172/jci.insight.169504}
}
EUVIMED